As part of PATH’s work in vaccine and pharmaceutical delivery technologies, this poster presents results from a user-acceptability study of two microarray patches (MAPs) in South Africa. The MAPs under assessment were designed for the self-administration of antiretrovirals, such as rilpilvirine, and may someday offer a discreet and effective form of PrEP protection for women at risk of HIV.